China's Biotech Boom Reshapes Global Drug Innovation and Investment
Chinese biotech shares have surged this year, driven by optimism over innovative cancer treatments being licensed to Western pharma companies, with notable deals like 3SBio's with Pfizer and Akeso's competitive PD-1 treatments, amidst a broader industry rebound and lower research costs, despite geopolitical uncertainties.